Skyrocketing demand for diabetes drug Mounjaro and obesity treatment Zepbound continues to drive record-breaking financial results for the firm.
Mounjaro sales reached $8.7 billion, while Zepbound added $4.2 billion, both exceeding market estimates despite lower realized prices.
The company now projects annual revenue between $82 billion and $85 billion as prescription volumes offset industry pricing pressures.
Lilly also celebrated the recent launch of Foundayo, the first once-daily weight-loss pill to receive federal approval.
Investors view the oral medication as a strategic expansion into a broader market of needle-hesitant patients worldwide.
The firm maintains a competitive edge through strong clinical data showing superior weight reduction compared to existing rival treatments.
CEO David Ricks credits the strong start to significant pipeline progress and increased manufacturing capacity for global markets.
Lilly continues to dominate the metabolic health sector, leveraging innovation to secure its position as a global leader.
